MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 ​ Statistically Significant Increase in Liver and Circulating FGF21 Expression ​ Greater Glucose Lowering and Comparable Weig

Event · Clinical / regulatory
Product
DA-1726
Indication
MetALD and ALD

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 16, 2026, 2:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 2:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$MTVA
Bullish
high confidence
Mentioned
$MTVA
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MTVABullishMed
01

Why it matters

The data could accelerate funding and partnership interest, while setting a benchmark for dual‑agonist programs.

02

Market read

First disclosure of significant preclinical data; may drive short‑term upside for MTVA.

03

What to watch

Potential safety concerns of glucagon activation and competition from established GLP‑1 drugs.

Relevance 8/10Novelty 8/10Timing: today

Background

MetaVia filed an 8‑K announcing preclinical efficacy of its lead candidate DA‑1726 against retatrutide.

Company-level read

Ticker impact

$MTVABullishHigh confidence
Context

MetaVia disclosed positive preclinical data for DA-1726, showing superior glucose lowering and comparable weight loss versus retatrutide.

Expected impact

likely upward pressure as investors price in the differentiated metabolic profile.

Evidence & confidence

First disclosure of compelling data for a novel GLP‑1/GCGR dual agonist; biotech stocks typically rally on such breakthroughs.

Market effects

strengthens the GLP‑1/dual‑agonist space and may raise expectations for competing programs.

U.S. biotech sector could see modest gains.

limited to investors tracking metabolic disease therapeutics.

Counterpoint

Preclinical success does not guarantee clinical outcomes; investors may wait for Phase 2 data before committing.

Key entities

  • MetaVia Inc.

    Clinical‑stage biotech developing DA‑1726 for liver‑related cardiometabolic diseases.

  • DA‑1726

    GLP‑1/GCGR dual‑receptor agonist showing promising preclinical metabolic effects.

Related articles

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) presented preclinical data at ObesityWeek 2026, showing its drug DA-1726 increased liver FGF21 expression and achieved weight loss comparable to retatrutide with less food intake suppression. The company plans to start a Phase 2 study for MetALD and ALD in late 2027. DA-1726 demonstrated greater glucose lowering and favorable lipid effects. According to MetaVia, the results support DA-1726's potential in liver-related cardiometabolic diseases.

$MTVAMed

MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ ​ ​ MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update ​ Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD ​ Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Le

$MTVAMedAI 8/10

MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Inc. (MTVA) reported Q3 2026 financial results, highlighting positive interim data from its Phase 1 Part 3B study of DA-1726, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. The company plans to initiate a Phase 2 study in 2027. MetaVia also appointed Sarah Browne, M.D., as Chief Medical Officer. R&D expenses increased to $2.6M for Q3 2026, up from $1.9M in Q3 2025, driven by DA-1726 development.